Kidney Transplant – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms – Claims Data Analysis (US)
MARKET OUTLOOK
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, these patients must remain on immunosuppressive regimens for the duration of their life. However, these powerful agents come with considerable risks on top of their important benefits. This report examines how key immunosuppressive agents are used in induction and maintenance regimens for kidney transplant rejection prophylaxis.
Questions AnsweredUESTIONS ANSWERED
- What patient shares do key therapies and brands garner by line of therapy in the induction and maintenance phases? What are the quarterly trends in prescribing among induction- and maintenance-phase kidney transplant patients?
- How have different immunosuppressive agents been integrated into the treatment algorithm, and what are their sources of business?
- What percentage of kidney transplant patients switch to a different therapy after initiation and how quickly?
- What percentage of kidney transplant patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
PRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Content Highlights
Markets covered: United States.
Key companies: BMS, Novartis, Pfizer, Roche, Sanofi Genzyme, Teva.
Key drugs: Nulojix, Imuran, CellCept, Myfortic, Prograf, Astagraf XL, Envarsus XR, Neoral, Sandimmune, Rapamune, Zortress, Thymoglobulin, Atgam, Simulect.
Product DescriptionRODUCT DESCRIPTION
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Table of contents
- Kidney Transplant - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)
- Treatment Algorithms CDA | Kidney Transplant | US | March 2021
- Treatment Algorithms CDA Kidney Transplant US 2021 Dashboard
Dominika Rudnicka-Noulin, Ph.D., M.Sc., is a senior business insights analyst on the Cardiovascular, Metabolic, Renal, and Hematologic (CMRH) Disorders team at Clarivate. She has authored reports on heart failure, acute coronary syndrome, and NASH. Previously, Dr. Rudnicka-Noulin was an associate editor at Nature Communications, working in a variety of therapy areas. She also worked for three years as a postdoctoral research associate on a joint project between Imperial College London and MedImmune aimed at developing more-potent antibody-based drugs. She earned her Ph.D. at the Institut Pasteur in Paris, France, where her work was funded by the European Commission’s Marie Skłodowska-Curie Actions.